Online inquiry

IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5212MR)

This product GTTS-WQ5212MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Hairy cell leukemia (HCL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5212MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13969MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ15535MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UCB-7858
GTTS-WQ855MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ7214MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ3471MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ13328MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ10862MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ13164MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04518600
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW